8-K: Beyond Air Q3 Revenue Soars 105%, Extends Cash Runway

Beyond Air, Inc. reported a 105% year-over-year revenue increase to $2.2 million for its fiscal third quarter, alongside strategic corporate updates and an extended cash runway into 2027.

Summary

• Revenue increased 105% year-over-year to $2.2 million for the fiscal third quarter ended December 31, 2025.
• Gross profit improved to $0.3 million for the quarter, up from a gross loss of $0.2 million in the prior year.
• Net loss significantly decreased to ($7.3) million, or ($0.85) per share, compared to ($13.0) million, or ($2.96) per share, in the same period last year.
• Pro forma cash, cash equivalents, restricted cash, and marketable securities totaled $22.3 million, including $4.5 million net proceeds from a recent private placement, providing a cash runway into calendar 2027.
• Signed a binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS, with Beyond Air set to receive up to $32.5 million in cash, milestones, and 19.99% equity in XTL.
• Phase 1a data from the UNO program in solid tumors will be presented at the AACR Annual Meeting in April 2026.
• Maintained fiscal year 2026 revenue guidance of $8-10 million.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, driven by strong revenue growth, improved profitability metrics, and strategic moves to extend cash runway and monetize assets. While still unprofitable, the trajectory is clearly improving, and key clinical and regulatory milestones are progressing.

Positives

• Revenue increased by 105% year-over-year to $2.2 million in fiscal Q3 2026, demonstrating strong commercial momentum.
• Achieved a gross profit of $0.3 million, a significant improvement from a gross loss of $0.2 million in the prior year.
• Net loss decreased substantially to ($7.3) million from ($13.0) million year-over-year, and loss per share improved to ($0.85) from ($2.96).
• Reduced research and development expenses by 19% to $2.4 million and selling, general, and administrative expenses by 42% to $4.5 million.
• Secured $4.5 million in net proceeds from a private placement, extending the cash runway into calendar 2027.
• Strategic divestiture of 85% of NeuroNOS for potential consideration of up to $32.5 million, plus a 19.99% equity stake in XTL Biopharmaceuticals.
• Completed the first sale of LungFit PH systems to a VA Medical Center, opening a potential pathway for broader adoption.
• Expanded global LungFit PH distribution network to 40 countries, covering a population nine times greater than the U.S.
• Phase 1a data from the UNO program in solid tumors selected for presentation at the AACR Annual Meeting in April 2026, indicating clinical progress.

Negatives

• Despite significant improvements, the company continues to operate at a net loss of ($7.3) million for the quarter.
• Net cash burn, excluding financing activities, was $4.3 million in the fiscal quarter ended December 31, 2025.
• Total long-term debt outstanding was $22.0 million as of December 31, 2025, including a $12 million promissory note with a 15% interest rate.

Risks

• The ability to raise additional capital in the future.
• Uncertainty regarding the timing and results of future pre-clinical studies and clinical trials.
• Potential for regulatory authorities, including the FDA and comparable non-U.S. authorities, to delay or not grant approval for product candidates.
• The company's approach to discover and develop novel drugs is unproven and may not lead to efficacious or marketable products.
• Challenges in funding and executing further pre-clinical studies and clinical trials of product candidates.
• Difficulties in obtaining, maintaining, and protecting intellectual property utilized by products.
• Competition from other companies using similar technology or developing products for similar uses.
• Dependence on collaborators for development and commercialization efforts.

Future Outlook

The company expects to receive FDA clearance for its second-generation LungFit PH system before the end of calendar 2026, which is anticipated to accelerate market share gains. It also maintains its fiscal year 2026 revenue guidance of $8-10 million and projects its pro forma cash balance to provide a runway into calendar 2027. Clinical development continues with Phase 1a data from the UNO program in solid tumors to be presented in April 2026, and a Phase 1b combination therapy trial planned.

Management Comments

• "We exceeded $2.0 million in quarterly revenue which marks an important milestone as we continue scaling our business and building awareness of the benefits our tankless NO system delivers in real-world settings." Steve Lisi, CEO.
• "Our commercial performance reflects steady momentum, with 21% sequential quarterly growth and a 105% increase over the same quarter last year." Steve Lisi, CEO.
• "We will continue to grow our business with LungFit PH as we prepare for the FDA clearance of our second-generation LungFit PH system, which we expect to receive before the end of calendar 2026, subject to regulatory review." Steve Lisi, CEO.
• "We believe the significant enhancements, including reduced weight and footprint, simplified operation, longer service interval, and full compatibility with both air and ground transport, will dramatically accelerate market share gains and position Beyond Air as a global leader in hospital-based NO delivery." Steve Lisi, CEO.
• "We are excited that an abstract featuring Phase 1a data from Beyond Cancer's UNO program in solid tumors was selected to be presented at the AACR 2026 Annual Meeting in April. The team will present the latest exciting clinical data from this important trial." Steve Lisi, CEO.

Industry Context

StockSavvy.ai notes that the medical device and biopharmaceutical sectors are highly competitive, with innovation and regulatory approvals being critical drivers of success. Beyond Air's significant revenue growth for LungFit PH and expansion into new international markets suggest effective commercialization in the nitric oxide delivery space. The strategic divestiture of NeuroNOS allows the company to potentially unlock value from its pipeline while focusing on its core NO platforms. The progress in the UNO oncology program positions Beyond Air within the growing immuno-oncology field, where novel approaches to solid tumors are highly sought after.

Comparison to Industry Standards

• Beyond Air's 105% year-over-year revenue growth for LungFit PH significantly outpaces the average growth rates for established medical device companies, which typically range from 5-15% annually. For instance, companies like Masimo (MASI) or Inogen (INGN) in respiratory care often see single to low double-digit growth.
• The expansion of LungFit PH into 40 countries, covering a population of over 3 billion, demonstrates a rapid global market penetration strategy, comparable to early-stage global expansion efforts seen in successful medical technology firms like Penumbra (PEN) or Shockwave Medical (SWAV) in their respective niches.
• The strategic transaction involving NeuroNOS, where Beyond Air receives a combination of upfront cash, milestones, and equity, is a common strategy for biopharmaceutical companies to monetize non-core assets or de-risk early-stage programs, similar to deals seen with larger pharmaceutical companies acquiring or partnering with smaller biotech firms for specific pipeline assets.
• The presentation of Phase 1a data at a major conference like AACR (American Association for Cancer Research) is a standard and crucial milestone for oncology drug developers, indicating scientific validation and progression, akin to presentations by companies like Mirati Therapeutics (MRTX) or Relay Therapeutics (RLAY) at similar stages of clinical development.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased value through revenue growth, reduced losses, strategic asset monetization (NeuroNOS), and progress in clinical pipeline. Dilution from recent private placement.
• Employees: Appointment of new CFO and Board Chairman indicates continued strategic direction and potential for growth, which could positively impact employee morale and opportunities.
• Customers (Hospitals/VA Centers): Continued availability and expansion of LungFit PH, with an anticipated improved second-generation system, offers enhanced treatment options for patients with hypoxic respiratory failure.
• Patients: Progress in clinical trials for UNO program in solid tumors and continued development of LungFit systems offer potential future therapeutic options for respiratory illnesses and cancer.
• Creditors: Long-term debt of $22.0 million and a $12 million promissory note with a 15% interest rate represent obligations, but the extended cash runway and improved financial performance may reduce immediate concerns.

Next Steps

• Continue scaling the LungFit PH business.
• Prepare for FDA clearance of the second-generation LungFit PH system, expected before the end of calendar 2026.
• Present Phase 1a data from the UNO program in solid tumors at the AACR Annual Meeting in April 2026.
• Initiate Phase 1b trial for UNO combination therapy in solid tumors.
• Complete the acquisition of 85% of NeuroNOS by XTL Biopharmaceuticals.
• International submissions for LungFit PH remain on track with local partners.

Key Dates

Recommendation

The company demonstrated strong operational improvements with significant revenue growth and reduced net loss, coupled with strategic moves like the NeuroNOS divestiture and extended cash runway. However, it remains unprofitable with substantial long-term debt. While the outlook for the second-generation LungFit PH and UNO program is promising, these are future catalysts. The current financial position and ongoing need for capital suggest a 'hold' recommendation, awaiting further execution on regulatory approvals and sustained profitability before a stronger 'buy' signal.

Keywords

Beyond Air, XAIR, LungFit PH, Nitric Oxide, Medical Device, Biopharmaceutical, Q3 Earnings, Financial Results, NeuroNOS, XTL Biopharmaceuticals, UNO Program, Solid Tumors, FDA Approval, Corporate Update, Cash Runway, Healthcare, Respiratory Illnesses, Oncology